MX2022004515A - Metodo y composicion para aumentar la sintesis de proteinas musculares. - Google Patents
Metodo y composicion para aumentar la sintesis de proteinas musculares.Info
- Publication number
- MX2022004515A MX2022004515A MX2022004515A MX2022004515A MX2022004515A MX 2022004515 A MX2022004515 A MX 2022004515A MX 2022004515 A MX2022004515 A MX 2022004515A MX 2022004515 A MX2022004515 A MX 2022004515A MX 2022004515 A MX2022004515 A MX 2022004515A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- protein synthesis
- increasing muscle
- creatine
- muscle protein
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000008934 Muscle Proteins Human genes 0.000 title abstract 2
- 108010074084 Muscle Proteins Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000001243 protein synthesis Methods 0.000 title abstract 2
- 230000014616 translation Effects 0.000 title abstract 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 6
- 229960003624 creatine Drugs 0.000 abstract 3
- 239000006046 creatine Substances 0.000 abstract 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- -1 nitrogenous organic acid Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe un método y composición para aumentar la síntesis de proteínas musculares en mamíferos. En una modalidad, a los mamíferos se les administra una composición de construcción de proteínas que comprende un derivado de aminoácidos que incluye L-carnitina y un ácido orgánico nitrogenado que incluye creatina. En una modalidad particular, la creatina está en una forma de administración de cápsula resistente a ácidos. La relación de L-carnitina con respecto a creatina puede ser de alrededor de 10:1 a alrededor de 1:1. La composición de construcción de proteínas se puede administrar en una cápsula entérica monolítica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915709P | 2019-10-16 | 2019-10-16 | |
| US202063021766P | 2020-05-08 | 2020-05-08 | |
| PCT/US2020/056033 WO2021076926A1 (en) | 2019-10-16 | 2020-10-16 | Method and composition for increasing muscle protein synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004515A true MX2022004515A (es) | 2022-07-12 |
Family
ID=75538331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004515A MX2022004515A (es) | 2019-10-16 | 2020-10-16 | Metodo y composicion para aumentar la sintesis de proteinas musculares. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220370393A1 (es) |
| EP (1) | EP4027991A4 (es) |
| CA (1) | CA3153328A1 (es) |
| MX (1) | MX2022004515A (es) |
| WO (1) | WO2021076926A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022271922A1 (en) * | 2021-06-24 | 2022-12-29 | Lonza Greenwood Llc | Method to control administration of active substance to the digestive tract |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10119946A1 (de) * | 2001-04-24 | 2003-04-30 | Joachim Steuer | Zugabe von CLA(konjugierte Linolsäure) und/oder Kreatin und/oder L-Carnitin zu einer an sich üblichen Brausetablette |
| EP1762232A1 (en) * | 2005-09-09 | 2007-03-14 | Warner-Lambert Company LLC | Liquid filled delivery system, preferably an HPMC capsule filled with glycerol |
| US20100055178A1 (en) * | 2008-08-29 | 2010-03-04 | Adel Vilallobos | Enteric-coated creatine compositions and methods of use thereof |
| KR101762460B1 (ko) * | 2009-09-24 | 2017-07-27 | 캡슈겔 벨지엄 엔브이 | 내산성 캡슐 |
| US8828426B2 (en) * | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
| JP6626712B2 (ja) * | 2012-05-02 | 2019-12-25 | キャプシュゲル・ベルジウム・エヌ・ヴィ | 放出制御ポリマーの水性分散液並びにそのシェル及びカプセル |
| JP6196091B2 (ja) * | 2013-07-29 | 2017-09-13 | 三生医薬株式会社 | カプセル剤 |
| US20150366814A1 (en) * | 2014-06-23 | 2015-12-24 | Banner Life Sciences Llc | All-natural enteric soft capsules comprising active ingredients |
| JP6588193B2 (ja) * | 2014-07-31 | 2019-10-09 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ | カプセル製剤 |
| WO2017059101A1 (en) * | 2015-10-02 | 2017-04-06 | Amip, Llc | Composition for improved performance |
| JP2018537987A (ja) * | 2015-12-18 | 2018-12-27 | ロンザ インコーポレイテッド | 哺乳動物において筋タンパク質合成および／または機能強度を増大させる方法および組成物ならびに組成物を製造する方法 |
| US20170360735A1 (en) * | 2016-06-21 | 2017-12-21 | Dreampak | Ingestible emulsion matrix for delivery of creatine |
| WO2018035027A1 (en) * | 2016-08-15 | 2018-02-22 | Corr-Jensen Inc. | TIME RELEASE OF CoQ10 |
-
2020
- 2020-10-16 US US17/765,173 patent/US20220370393A1/en active Pending
- 2020-10-16 WO PCT/US2020/056033 patent/WO2021076926A1/en not_active Ceased
- 2020-10-16 MX MX2022004515A patent/MX2022004515A/es unknown
- 2020-10-16 EP EP20877165.9A patent/EP4027991A4/en active Pending
- 2020-10-16 CA CA3153328A patent/CA3153328A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4027991A4 (en) | 2023-11-22 |
| US20220370393A1 (en) | 2022-11-24 |
| CA3153328A1 (en) | 2021-04-22 |
| EP4027991A1 (en) | 2022-07-20 |
| WO2021076926A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11786496B2 (en) | Composition and methods for treating intestinal hyperpermeability | |
| MX2023011456A (es) | Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| WO2017171535A3 (en) | Compositions | |
| MY156305A (en) | Pharmaceutical composition | |
| US20150111878A1 (en) | Compositions and methods for treating intestinal hyperpermeability | |
| SI2150538T1 (sl) | Novi substituirani hidantoini | |
| NZ594067A (en) | VISFATIN THERAPEUTIC AGENTS (PEPTIDES, siRNA, FK-866, APO866 ) FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS | |
| MY205382A (en) | Novel peptide compound or pharmaceutically acceptable salt thereof | |
| MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
| MX2021015966A (es) | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. | |
| EP4400098A3 (en) | Co-amorphous forms of beta-lactoglobulin and a drug substance | |
| EA202192925A1 (ru) | Твердые формы ингибитора glyt1 | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| MX2022004515A (es) | Metodo y composicion para aumentar la sintesis de proteinas musculares. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| TW200735863A (en) | Dietary compositions for enhancing metabolism and reducing reactive oxygen species | |
| WO2019008551A3 (en) | TRITERPENOID ENRICHED COATED COSTUS COMPOSITION AND PROCESS FOR PREPARING THE SAME | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| MX2022004516A (es) | Metodo y composicion para aumentar la sintesis de proteinas musculares. | |
| ATE536342T1 (de) | Neue carbamoylglycinderivate | |
| EP4356961A3 (en) | Use of whey protein micelles for controlling postprandial glucose response | |
| ZA202302893B (en) | Agonists of stimulator of interferon genes sting | |
| RU2008138124A (ru) | Способ профилактики и лечения заболеваний, вызванных штаммами субтипа h5n1 вируса гриппа птиц, с использованием индуктора интерферона и ингибитора нейраминидазы | |
| EA202193006A1 (ru) | Изопропиловый эфир [((1r,2s,5r)-2-изопропил-5-метилциклогексанкарбонил)амино]уксусной кислоты для лечения хронического кашля |